Gossamer Bio Inc GOSS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
-
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
-
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
-
Gossamer Bio Announces 1-for-80 Reverse Stock Split
-
Gossamer Bio to Present at Cantor Global Healthcare Conference
-
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
-
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
-
Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm
Trading Information
- Previous Close Price
- $9.79
- Day Range
- $9.64–9.86
- 52-Week Range
- $8.27–309.20
- Bid/Ask
- $9.58 / $9.71
- Shares Outstanding
- 6.12M
- Market Cap
- $60.40M
- Volume/Avg
- 32,137 / 368,199
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 162
- Website
- https://www.gossamerbio.com
Valuation
|
Metric
|
GOSS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.59 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GOSS
|
|---|---|
Quick Ratio | 0.46 |
Current Ratio | 0.53 |
Interest Coverage | −10.59 |
Quick Ratio
GOSS
Profitability
|
Metric
|
GOSS
|
|---|---|
Return on Assets (Normalized) | −88.95% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −200.14% |
Return on Assets
GOSS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|m>!N^k^ | LOCK|>?&s | $133B | |||
| Moderna Inc
MRNA
| LOCK|HBHxV% | LOCK|&^ | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|vKR#%% | LOCK|f&zBp | $83B | |||
| argenx SE ADR
ARGX
| LOCK|>RV#N< | LOCK|?%& | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|R%Vzmk | LOCK|@v? | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$HmTQx | LOCK|$!@%B | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|CwDW&@X? | LOCK|Q?BN | $28B | |||
| Incyte Corp
INCY
| LOCK|r?j$W# | LOCK|!G | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Rsq?%! | LOCK|j! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|S<gK$G | LOCK|Q&$ | $14B |
United States